Integration of small-molecule discovery in academic biomedical research

Mount Sinai Journal of Medicine

Volumn 77, Issue 4, 2010, Pages 350-357

  Ohlmeyer, Michael ^a   Zhou, Ming Ming ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemical screening; Drug discovery; Medicinal chemistry; Small molecule

Indexed keywords

CELL PROTEIN;

CHEMISTRY; DRUG TARGETING; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL RESEARCH; MOLECULE; PROTEIN TARGETING; REVIEW; SCREENING; VALIDATION STUDY;

BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SMALL MOLECULE LIBRARIES; UNIVERSITIES;

EID: 77954977329     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20197     Document Type: Review

References (44)

1. Verkman AS. Drug discovery in academia. Am J Physiol Cell Physiol 2004; 286: C465-C474.
2. Wyatt PG. The emerging academic drug-discovery sector. Future Med Chem 2009; 1: 1013-1017.
3. Kozikowski AP, Roth B, Tropsha A. Why academic drug discovery makes sense. Science 2006; 313:1235-1236. (Pubitemid 44330930)
4. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 727-730.
5. Kubinyi H. Drug research: myths, hype and reality. Nat Rev Drug Discov 2003; 2: 665-668. (Pubitemid 37368830)
6. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl 2003; 42: 2462-2481. (Pubitemid 36753413)
7. Sanchez R, Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel 2009; 12: 659-665.
8. Taverna SD, Li H, Ruthenberg AJ, et al. How chromatinbinding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007; 14: 1025-1040. (Pubitemid 350060344)
9. Mujtaba S, He Y, Zeng L, et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 2002; 9: 575-586. (Pubitemid 34273788)
10. Mujtaba S, He Y, Zeng L, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004; 13: 251-263. (Pubitemid 38183271)
11. FischleW, Wang Y, Jacobs SA, et al. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev 2003; 17: 1870-1881.
12. Huang B, Yang XD, Zhou MM, et al. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009; 29: 1375-1387.
13. Zeng L, Li J, Muller M, et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc 2005; 127: 2376-2377.
14. Sachchidanand, Resnick-Silverman L, Yan S. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 2006; 13: 81-90.
15. Pan C, Mezei M, Mujtaba S, et al. Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding proteinassociated factor. J Med Chem 2007; 50: 2285-2288.
16. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996; 274: 1531-1534.
17. Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins. Science 1997; 278: 497-499.
18. Hajduk PJ, Gerfin T, Boehlen JM, et al. High-throughput nuclear magnetic resonance-based screening. J Med Chem 1999; 42: 2315-2317. (Pubitemid 29305164)
19. Moore JM. NMR screening in drug discovery. Curr Opin Biotechnol 1999; 10: 54-58.
20. Dobson CM. Chemical space and biology. Nature 2004; 432: 824-828.
21. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature 2004; 432: 855-861. (Pubitemid 40037141)
22. Goodnow RA Jr, Gillespie P. Hit and lead identification: efficient practices for drug discovery. Prog Med Chem 2007; 45: 1-61.
23. Keseru GM, Makara GM. Hit discovery and hit-to-lead approaches. Drug Discov Today 2006; 11: 741-748.
24. Gribbon P. High-throughput hit finding and compound-profiling technologies for academic drug discovery. Drug Discov Today Tech 2008; 5: e3-e7.
25. Leeson PD, Springthorpe B. The influence of drug-like concepts on desision-making in medicinal chemistry. Nat Rev Drug Discov 2007; 6: 881-890. (Pubitemid 350042396)
26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26. (Pubitemid 33653411)
27. Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or priveleged substructures. Chem Rev 2003; 103: 893-930.
28. Nandy JP, Prakesch M, Khadem S, et al. Advances in solution-and solid-phase synthesis toward the generation of natural product-like libraries. Chem Rev 2009; 109: 1999-2060.
29. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-1662.
30. Inglese J, Johnson RL, Simeonov A, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 2007; 3: 466-479. (Pubitemid 47080373)
31. Lazo JS, Brady LS, Dingledine R. Building a pharmacological lexicon: small molecule discovery in academia. Mol Pharmacol 2007; 72: 1-7. (Pubitemid 46998519)
32. Lang P, Yeow K, Nichols A, Scheer A. Cellular imaging in drug discovery. Nat Rev Drug Discov 2006; 5: 343-356.
33. Krausz E. High-content siRNA screening. Mol Biosyst 2007; 3: 232-240.
34. Stockwell BR. Exploring biology with small organic molecules. Nature 2004; 432: 846-854.
35. Bauer A, Stockwell B. Neurobiological applications of small molecule screening. Chem Rev 2008; 108: 1774-1786. (Pubitemid 351796409)
36. Spring DR. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev 2005; 34: 472-482.
37. Owicki JC. Fluoresence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000; 5: 297-306.
38. Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006; 11: 607-615.
39. McGovern SL, Helfand BT, Feng B, Shoichet BK. A specific mechanism of nonspecific inhibition. J Med Chem 2003; 46: 4265-4272.
40. Raveglia LF, Giardina GAM. Accelerating the drugdiscovery process: new tools and technologies available to medicinal chemists. Future Med Chem 2009; 1: 1019-1023.
41. Kirschning A, Monenschein H, Wittenberg R. Functionalized polymers - emerging versatile tools for solution-phase chemistry and automated parallel synthesis. Angew Chem Int Ed Engl 2001; 40: 650-679. (Pubitemid 32179720)
42. Ley SV, Baxendale IR. New tools and concepts for modern organic synthesis. Nat Rev Drug Discov 2002; 1: 573-586. (Pubitemid 37361521)
43. Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007; 3: 641.
44. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007; 6: 636-649.